Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma

British Journal of Surgery

Volumn 83, Issue 3, 1996, Pages 336-340

  Yamamoto, M ^a,b   Arii, S ^b   Sugahara, K ^a   Tobe, T ^b  

^a Yamanashi Medical University   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARMOFUR;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; HUMAN; LIVER CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; NEUROPATHY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TIME FACTORS;

EID: 0030012773     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800830313     Document Type: Article

References (12)

1. Kanematsu T, Matsumata T, Takenaka K, Yoshida Y, Higashi H, Sugimachi K. Clinical management of recurrent hepatocellular carcinoma after primary resection. Br J Surg 1988; 75: 203-6.
2. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991; 214: 114-17.
3. Yamamoto M, Matsuda M, Iimuro Y, Fujii H, Nagahori K, Ainota T. Intrahepatic distant metastasis and metachronous multicentric occurrence in solitary hepatocellular carcinoma of less than five centimeters in diameter. Surg Today 1993; 23: 969-78.
4. Yamamoto M, Iimuro Y, Mogaki M, Kachi K, Fujii H, Matsumoto Y. Prediction of recurrence after HCC resection. Faint oily deposits on preoperative Lipiodol-CT of remnant liver tissue. Acta Radiol 1994; 35: 329-34.
5. Union Internacional Contra la Cancrum. Liver (ICD-0 155). In: Hermanek P, Sobin LH, eds. TNM Classification of Malignant Tumours. 4th ed. Berlin: Springer, 1987: 53-5.
6. Ikeda K, Kumada H, Arase Y el al. Risk factors for side effects of long-term administration of 5-fluorouracil derivatives in patients with hepatocellular carcinoma associated with liver cirrhosis - relationship with serum concentration of anti-tumor agents and side effects. Nippon Shokakibyo Gakkai Zasshi 1988; 85: 2411-19.
7. Takenaka K, Kanematsu T, Shimada M, Sugimachi K. Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol 1989; 25: 1191-5.
8. Iigo M, Kuretani K, Hoshi A. Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil and 5-fluorouracil in mice bearing ascites sarcoma 180. J Natl Cancer Inst 1981; 66: 345-9.
9. Yamamoto M, Sugahura K. Overview of the general rules for the clinical and pathological study of primary liver cancer in Japan. In: Tobe T, Kameda H, Okudaira M et al., eds. Primary Liver Cancer in Japan. Tokyo: Springer, 1992: 385-92.
10. Aoki N. Reversible leukoencephalopathy caused by 5-fluorouracil derivatives, presenting as akinetic mutism. Surg Neurol 1986; 25: 279-82.
11. Edmondson HA, Steiner PE. Primary carcinoma of the liver. A study of 100 cases among 48 900 necropsies. Cancer 1954; 7: 462-503.
12. Liver Cancer Study Group of Japan. Summary of the data from a follow-up study by the Liver Cancer Study Group of Japan. In Tobe T, Kameda H, Okudaira M et al., eds. Primary Liver Cancer in Japan. Tokyo: Springer, 1992: 445-53.